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Many normal cells respond to certain stresses, such as oncogene activation, by undergoing a permanent form of growth arrest 
known as senescence, an intrinsic tumor suppressor program. The predominant view has been that senescence is caused in 
some settings through a mutant oncogene’s ability to induce activation of high levels of sustained MAP kinase and PI3 kinase 
signaling. A new study in this issue of Cancer Cell has challenged this model with the surprising finding that aberrant activa-
tion of the RAS/RAF pathway can induce a negative feedback loop that globally attenuates MAPK and PI3K signaling and that 
the reduction of signaling in these pathways is required for senescence.The aberrant activation of the RAS/PI3K 
pathways is a potent oncogenic event 
that can result from activating mutations 
of oncogenes or inactivation of certain 
tumor suppressor genes. While these 
simple genetic events pose significant 
risks for cancer development, mammals 
have evolved an effective strategy to 
control such would-be cancer cells via 
a few mechanisms, including oncogene-
induced senescence (OIS). While sev-
eral recent reports have proven that OIS 
is not a mere artifact of cell culture and 
have established the importance of OIS 
in vivo in mammalian tumor suppression 
(reviewed in Narita and Lowe, 2005), the 
molecular mechanics of OIS, as opposed 
to other forms of growth arrest, are not 
fully understood. A new report in this 
issue of Cancer Cell (Courtois-Cox et al., 
2006) suggests a surprising mechanism 
for this process involving a negative feed-
back network that significantly attenuates 
RAS/PI3K signaling in primary cells with 
mutations in this pathway.
The initial description of OIS came 
from a landmark study by Serrano and 
colleagues using activated RAS in cul-
tured cells (Serrano et al., 1997). This 
report showed that mutant RAS expres-
sion in primary fibroblasts induced OIS 
and that, to achieve transformation, fibro-
blasts had to bypass OIS through genet-
ic events leading to compromise of the 
p16INK4A-RB and/or ARF-p53 pathways. A 
number of recent studies have supported 
the biological relevance of this process by 
showing that precancerous lesions of the 
lung, prostate, and melanocytes exhibit 
senescence-like features in humans and 
mice, thereby indicating that OIS traps 
cells with potentially cancer-causing 
mutations in a growth-arrested state in 
intact organisms (reviewed in Narita and 
Lowe, 2005; see also Gray-Schopfer et 
al., 2006). A particularly compelling dem-
onstration is the finding that human dys-
plastic nevi (cutaneous moles) appear cancer cell 10, December 2006 © 2006 elsesenescent, yet such lesions are found 
in children and persist in some cases 
through old age. Therefore, senescence 
appears to ward off cancer even in the 
youngest of humans, and senescent cells 
may persist a human lifetime.
The hallmarks of OIS include p16INK4A 
expression, which activates RB; p53 
pathway activation; and the formation of 
characteristic nuclear structures known 
as senescence-associated heterochro-
matin foci (SAHF). The ability of MAPK 
and PI3K signaling to activate the ARF-
p53 and p16INK4A-RB tumor suppressor 
pathways, coupled with a role for RB in 
directing alterations in chromatin archi-
tecture, appears to explain, in part, these 
properties. Hence, aberrant high levels 
of MAPK or PI3K signaling were thought 
to be a driving force in senescence. 
In accord with this view, OIS can be 
blocked by inhibitors of MAPK signaling 
(Satyanarayana et al., 2004) or growth 
in low serum (which presumably reduc-
es mitogenic drive) (Takahashi et al., 
2006). Therefore, senescence appears 
to result from potent mitogenic stimula-
tion in the face of a persistent p16INK4A- 
or p53-mediated antiproliferative signal. 
The relationship of OIS to other forms of 
senescence—such as replicative senes-
cence, which results from telomere dys-
function—is not completely understood, 
although these processes show both 
phenotypic and biochemical similarity.
The current report (Courtois-Cox 
et al., 2006) suggests a new model to 
explain OIS. The authors cleverly induce 
RAS activation in primary human fibro-
blasts by depletion of NF1, a protein that 
converts RAS to its inactive GDP-bound 
form. A strength of this approach is that 
it does not rely on the ectopic expression 
of RAS. In the setting of reduced NF1, 
RAS activation produced a marked, but 
transient, activation of the downstream 
ERK and AKT pathways followed by a 
profound shutdown of this signaling tem-vier inc. porally accompanied by the appearance 
of senescence (Figure 1A). This global 
abrogation of ERK and PI3K signaling is 
associated with the activation of a broad 
transcriptional program of negative reg-
ulators of the RAS pathway, including 
Sproutys, RasGAPs, and DUSP6/MKP3 
(an ERK phosphatase). The authors 
observed a similar response following 
ectopic expression of mutant RAS or of 
mutant B-RAF, a downstream target of 
RAS that activates ERK MAPK signal-
ing, showing that these effects were not 
specific to NF1 deletion. Additionally, the 
authors confirmed many of their findings 
using small-molecule inhibitors of ERK 
or PI3K signaling. Curiously, the authors 
also show that abnormal activation of 
PI3K signaling also leads to senescence, 
a result suggesting that different circuit-
ries mediate OIS depending on the incit-
ing oncogene.
To document these processes in 
human patients, the authors turned to 
the study of tumors from human patients 
with neurofibromatosis type I, an auto-
somal dominant syndrome that results 
from inheritance of a single mutant allele 
of nf1. In such patients, characteristic 
tumors (e.g., neurofibromas) occur when 
there is somatic loss of the nonmutant 
nf1 allele, which leads to RAS activation. 
In accord with the authors’ hypotheses, 
however, such tumors generally have low 
malignant potential (e.g., the lifetime risk 
of a malignant nerve tumor in a patient 
with neurofibromatosis type I is ?10%). 
Correspondingly, the authors show that 
tumors from neurofibromatosis type I 
patients exhibit features of senescence 
(e.g., increased p16INK4A expression and 
senescence-associated β-galactosidase 
activity). This result is consistent with the 
aforementioned studies showing OIS in 
intact organisms and is the first clear-cut 
demonstration of OIS in vivo in humans 
in a nonmelanocytic tissue. Therefore, 
these data suggest that OIS in response 451
	 p r e v i e w sFigure 1. Two models of oncogene-induced senescence
a: Activated rAs leads to growth arrest as a result of potent negative feedback that abrogates erK 
and Pi3K signaling. The red lines indicate negative feedback signals. 
B: rAs activation induces DnA damage via the production of rOs, which has been suggested to induce 
senescence through a few disparate mechanisms. These models differ in biochemical emphasis but 
are not mutually exclusive.to acute nf1 inactivation occurs in humans 
and is a barrier to malignancy in patients 
with neurofibromatosis type I. A caveat to 
this finding, however, is that many patients 
with neurofibromatosis type I suffer sig-
nificant morbidity from persistent growth 
of neurofibromas, even in the absence 
of frank progression to malignancy. 
Therefore, reasonably common, but as 
yet unknown, mechanisms to escape OIS 
must exist in the setting of homozygous 
nf1 inactivation.
It should be noted, however, that other 
models of OIS have also been advanced 
(Figure 1B). For example, several lines 
of experimentation have suggested that 
the generation of reactive oxygen spe-
cies (ROS) (Lee et al., 1999), and pos-
sibly a persistent DNA damage response 
(reviewed in von Zglinicki et al., 2005), 
are crucial features of senescence, yet 
it is not obvious how attenuated ERK 
and PI3K signaling would produce high 
levels of ROS or an ongoing DNA dam-
age response. Moreover, one wonders 
how lesions of tumor suppressors such 
as p16INK4A and/or p53 permit cells with 
oncogenic mutations to grow despite neg-
ative feedback. Such lesions indisputably 
render certain cells somewhat resistant to 
OIS (Serrano et al., 1997), but inactivation 
of these tumor suppressors would not be 452 expected to restore ERK or PI3K signaling 
in an obvious way. In contrast to this work, 
Soengas and colleagues have recently 
suggested that certain forms of RAS acti-
vation induce a p16INK4A/p53-independent 
senescence that requires sensors of stress 
in the endoplasmic reticulum (Denoyelle 
et al., 2006), and this form of senescence 
may differ entirely from that described by 
Courtois-Cox et al. Finally, Ferbeyre and 
colleagues have also reported a decrease 
in ERK signaling in the setting of RAS-
induced senescence (Gaumont-Leclerc et 
al., 2004), but in their report, altered ERK 
localization rather than decreased phos-
phorylation appears to be the mechanism 
of attenuation in MAPK signaling. Several 
possible explanations exist that could rec-
oncile these disparate findings (e.g., dif-
ferences in type of senescence, activated 
oncogene, or cell type), and clearly further 
studies will be needed to integrate these 
various models of OIS.
In summary, Courtois-Cox et al. show 
that a profound attenuation of ERK and 
PI3K signaling after RAS activation is 
required for OIS. Additionally, they pro-
vide evidence that OIS occurs in vivo in 
response to nf1 inactivation. This pro-
vocative report raises important future 
questions. For example, does negative 
feedback contribute to the persistence of senescence? It has been difficult to 
reverse OIS in human cells harboring 
SAHF (Beausejour et al., 2003; Takahashi 
et al., 2006), as such cells harbor wide-
spread alterations in chromatin struc-
ture that prevent the transcription of 
genes needed for cell cycle traversal. 
Additionally, it has recently been sug-
gested that ROS accumulate in senes-
cent cells to produce a durable block in 
cytokinesis (Takahashi et al., 2006). Given 
these features, one doubts that OIS could 
be reverted merely by restoring ERK and/
or PI3K signaling in truly senescent cells, 
but time will tell. More importantly, could 
therapeutic opportunity be derived from 
these findings? Perhaps the concomitant 
deprivation of ERK and PI3K signaling 
might induce senescence in established 
tumors harboring oncogenic lesions. With 
the advent of several potent, small-mol-
ecule inhibitors of these pathways directly, 
pharmacologic answers to this question in 
humans should be shortly forthcoming.
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Since the early days of microarray technol-
ogy, numerous investigators have analyzed 
clinical cohorts of human breast cancers in 
order to better understand disease patho-
genesis, and to provide a molecular expla-
nation for the heterogeneity in the outcome 
and therapeutic response of breast cancer 
patients. A PubMed search identifies 827 
publications with the keywords “microarray” 
and “breast cancer.” Most of the research 
has focused on the characterization of tran-
scriptional profiles of breast cancer (Table 1). 
For example, Perou et al. (2000) and Sørlie 
et al. (2001) established the classification of 
breast tumors into five different phenotypic 
subtypes. van ’t Veer et al. (2002) and van 
de Vijver et al. (2002) divided breast can-
cer patients into those with favorable and 
unfavorable outcome with high accuracy, 
suggesting the potential of microarrays 
as a diagnostic test to select patients who 
would need adjuvant therapies. Many other 
studies have also identified gene signatures 
predictive of distant metastasis or survival 
(Wang et al., 2005; Naderi et al., 2006). 
Several authors have also studied profiles 
of genomic DNA copy numbers (Hicks et al., 
2005; Bergamaschi et al., 2006; Fridlyand 
et al., 2006) using array-based comparative 
genomic hybridization (CGH). These studies 
have identified numerous specific genetic 
alterations and have also defined subtypes 
of breast cancers at the genomic level.
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prototype HER2 oncogene, are activated 
by recurrent gene amplifications in breast 
cancer and may show an association with 
aggressive tumor types. Many of these are 
potentially druggable by small-molecule 
inhibitors. For example, two potential amplifi-
cation targets, the GRB7 and PNMT genes, 
reside in the HER2 amplicon at 17q12 and 
are coactivated in breast cancer with HER2. 
Their targeting could provide synergistic 
therapeutic responses with Her2 inhibition 
or contribute to poor responses against 
Herceptin (Kao and Pollack, 2006).
Clinical tumor profiling is informative 
but at best associative in nature. In order 
to identify causative links between genes 
and tumor phenotypes, it is necessary to 
use cell lines. The Neve et al. (2006) paper 
describes the DNA and RNA microarray 
profiling data for a comprehensive resource 
of 51 different breast cancer cell lines, 
t challenge. Two studies in this issue of 
les of 145 primary breast cancers and 51 
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